Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 10, 2026, 4:04 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Androgen-deprivation Therapy Clear all
Completed Not applicable Interventional

A Pilot Study of Physical Activity for Improving Quality of Life in Prostate Cancer Patients on Androgen Deprivation Therapy (ADT)

NCT00853164
View directory record Official record
Conditions
Prostate Cancer
Interventions
walking exercise, weight training, Usual Care
Behavioral
Lead sponsor
Washington University School of Medicine
Other
Eligibility
40 Years to 80 Years · Male only
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated May 6, 2018 · Synced Jun 10, 2026, 4:04 AM EDT
Withdrawn Phase 2 Interventional

Androgen Deprivation Therapy and Apalutamide With or Without Radiation Therapy for the Treatment of Biochemically Recurrent Prostate Cancer, RESTART Study

NCT04585932
View directory record Official record
Conditions
Biochemically Recurrent Prostate Carcinoma, Metastatic Prostate Carcinoma, Oligometastatic Prostate Carcinoma, Stage IV Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8
Interventions
Apalutamide, Degarelix, Leuprolide Acetate, Quality-of-Life Assessment, Questionnaire Administration, Radiation Therapy
Drug · Other · Radiation
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 19, 2021 · Synced Jun 10, 2026, 4:04 AM EDT
Completed Not applicable Interventional Results available

Docetaxel, Androgen Deprivation and Proton Therapy for High Risk Prostate Cancer

NCT01040624
View directory record Official record
Conditions
Prostate Cancer
Interventions
> 15% risk of + LN
Radiation
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older · Male only
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2022
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Oct 2, 2023 · Synced Jun 10, 2026, 4:04 AM EDT
Completed Phase 3 Interventional Results available

Hormone Therapy, Radiation Therapy, and Steroid 17alpha-monooxygenase TAK-700 in Treating Patients With High-Risk Prostate Cancer

NCT01546987
View directory record Official record
Conditions
Prostate Cancer
Interventions
GnRH agonist, Anti-androgen, TAK-700, Radiation therapy
Drug · Radiation
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years and older · Male only
Enrollment
239 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2025
U.S. locations
165
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 136 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2026 · Synced Jun 10, 2026, 4:04 AM EDT
Active, not recruiting Phase 2 Interventional Results available

A Study of Salvage Radiotherapy With or Without Enzalutamide in Recurrent Prostate Cancer Following Surgery

NCT03809000
View directory record Official record
Conditions
Prostate Cancer
Interventions
Radiation Therapy, Enzalutamide, Bicalutamide, GnRH analog
Radiation · Drug
Lead sponsor
RTOG Foundation, Inc.
Other
Eligibility
18 Years and older · Male only
Enrollment
188 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2029
U.S. locations
106
States / cities
Gilbert, Arizona • Peoria, Arizona • Phoenix, Arizona + 89 more
Source: ClinicalTrials.gov public record
Updated Dec 29, 2025 · Synced Jun 10, 2026, 4:04 AM EDT
Completed Phase 1Phase 2 Interventional

CP-675,206 With Neoadjuvant Hormone Therapy in Patients With High Risk Prostate Cancer

NCT00075192
View directory record Official record
Conditions
Prostatic Neoplasms
Interventions
CP-675,206 and leuprolide acetate and bicalutamide, leuprolide acetate and bicalutamide
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older · Male only
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
11
States / cities
La Masa, California • Washington D.C., District of Columbia • Gallatin, Tennessee + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 5, 2012 · Synced Jun 10, 2026, 4:04 AM EDT
Withdrawn Phase 3 Interventional

Pioglitazone and Insulin Resistance in ADT

NCT05098327
View directory record Official record
Conditions
Prostate Cancer, Insulin Resistance, Diabetes Mellitus, Type 2, Androgen Deficiency
Interventions
Pioglitazone 30 mg, Placebo
Drug
Lead sponsor
State University of New York at Buffalo
Other
Eligibility
18 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Aug 14, 2023 · Synced Jun 10, 2026, 4:04 AM EDT
Completed No phase listed Observational

Influence of Hormone Therapy on Heart Attack Incidence in Men Undergoing Prostate Brachytherapy

NCT00651222
View directory record Official record
Conditions
Prostate Cancer, Cardiovascular Death
Interventions
No intervention was required
Other
Lead sponsor
Prostate Cancer Foundation of Chicago
Other
Eligibility
Male only
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Westmont, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 1, 2008 · Synced Jun 10, 2026, 4:04 AM EDT
Active, not recruiting Phase 2 Interventional

Dose-Escalated Proton Radiation Therapy for High-Risk Prostate Cancer

NCT03624660
View directory record Official record
Conditions
Adenocarcinoma of the Prostate
Interventions
HR-A, HR-B
Radiation
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 100 Years · Male only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2028
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Feb 9, 2026 · Synced Jun 10, 2026, 4:04 AM EDT
Recruiting Phase 2 Interventional

The University of Miami Adapt (UAdapt) Trial

NCT06111313
View directory record Official record
Conditions
Prostate Cancer
Interventions
FTLEAD, Ultra-Short-Term Androgen Deprivation Therapy with Relugolix, HypoLEAD, ADT Standard of Care
Radiation · Drug
Lead sponsor
University of Miami
Other
Eligibility
35 Years to 85 Years · Male only
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2033
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Feb 17, 2026 · Synced Jun 10, 2026, 4:04 AM EDT
Completed Phase 2 Interventional

Study of Effectiveness of IMC-A12 Antibody Combined With Hormone Therapy Prior to Surgery to Treat Prostate Cancer

NCT00769795
View directory record Official record
Conditions
Prostate Cancer
Interventions
IMC-A12, Bicalutamide, Goserelin
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older · Male only
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
3
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Mar 28, 2017 · Synced Jun 10, 2026, 4:04 AM EDT
Completed Phase 2 Interventional

Neoadjuvant Androgen Deprivation Therapy Combined With Enzalutamide and Abiraterone Using Multiparametric MRI and 18FDCFPyL PET/CT in Newly Diagnosed Prostate Cancer

NCT03860987
View directory record Official record
Conditions
Castrate Sensitive Prostate Cancer
Interventions
goserelin, Enzalutamide, Abiraterone, 18F-DCFPyL, Prednisone, Radical Prostatectomy
Drug · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 99 Years · Male only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated May 21, 2026 · Synced Jun 10, 2026, 4:04 AM EDT
Completed Phase 3 Interventional Results available

S1216, Phase III ADT+TAK-700 vs. ADT+Bicalutamide for Metastatic Prostate Cancer

NCT01809691
View directory record Official record
Conditions
Prostate Cancer
Interventions
TAK-700, Bicalutamide
Drug
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older · Male only
Enrollment
1,313 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2025
U.S. locations
560
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 374 more
Source: ClinicalTrials.gov public record
Updated Dec 30, 2025 · Synced Jun 10, 2026, 4:04 AM EDT
Completed Phase 2 Interventional

Androgen Suppression Plus Radiation Therapy in Treating Patients With Prostate Cancer

NCT00006359
View directory record Official record
Conditions
Prostate Cancer
Interventions
LHRH agonist, antiandrogen, radiation therapy, Brachytherapy boost
Drug · Radiation
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years to 120 Years · Male only
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2012
U.S. locations
26
States / cities
Lewes, Delaware • Newark, Delaware • Wilmington, Delaware + 18 more
Source: ClinicalTrials.gov public record
Updated Jul 17, 2016 · Synced Jun 10, 2026, 4:04 AM EDT
Completed Phase 2 Interventional

Combining EPI-7386 With Enzalutamide and Androgen Deprivation Therapy for Metastatic Hormone-Sensitive Prostate Cancer

NCT06312670
View directory record Official record
Conditions
Metastatic Hormone-sensitive Prostate Cancer (mHSPC), Prostate Cancer, Prostate Adenocarcinoma
Interventions
EPI-7386, Enzalutamide, Androgen Deprivation Therapy (ADT)
Drug
Lead sponsor
Pedro Barata, MD, MSc
Other
Eligibility
19 Years and older · Male only
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
2
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated May 28, 2025 · Synced Jun 10, 2026, 4:04 AM EDT
Active, not recruiting Phase 2 Interventional

Comeback From Long coursE Androgen Deprivation Therapy (ADT) With RElugolix and Darolutamide (CLEARED)

NCT06463457
View directory record Official record
Conditions
Prostate Cancer, Advanced Prostate Cancer, Hormone Sensitive Prostate Cancer
Interventions
Darolutamide, Relugolix
Drug
Lead sponsor
Atish Choudhury, MD
Other
Eligibility
18 Years and older · Male only
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
3
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 8, 2026 · Synced Jun 10, 2026, 4:04 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Hormone Therapy and Intensity-Modulated Radiation Therapy in Treating Patients With Metastatic Prostate Cancer

NCT00544830
View directory record Official record
Conditions
PSA Level Greater Than Two, Stage IV Prostate Adenocarcinoma AJCC v7
Interventions
Bicalutamide, Goserelin Acetate, Intensity-Modulated Radiation Therapy, Laboratory Biomarker Analysis, Leuprolide Acetate
Drug · Radiation · Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older · Male only
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2027
U.S. locations
2
States / cities
Duarte, California • South Pasadena, California
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Jun 10, 2026, 4:04 AM EDT
Completed Phase 2 Interventional Results available

Abiraterone Prednisone and Hormonal Therapy Before and During Radiation Therapy in Localized Prostate Cancer

NCT01023061
View directory record Official record
Conditions
Adenocarcinoma of the Prostate, Stage II Prostate Cancer, Stage III Prostate Cancer, Stage IV Prostate Cancer
Interventions
abiraterone acetate, prednisone, leuprolide acetate, laboratory biomarker analysis, external beam radiation therapy, goserelin acetate
Drug · Other · Radiation
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older · Male only
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
2
States / cities
Seattle, Washington • Tacoma, Washington
Source: ClinicalTrials.gov public record
Updated Jun 5, 2017 · Synced Jun 10, 2026, 4:04 AM EDT
Terminated Phase 3 Interventional Results available

Trial of ADT and SBRT Versus SBRT for Intermediate Prostate Cancer

NCT03056638
View directory record Official record
Conditions
Prostate Cancer
Interventions
Degarelix, stereotactic body radiosurgery (SBRT)
Drug · Radiation
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
10
States / cities
Miami, Florida • Basking Ridge, New Jersey • Middletown, New Jersey + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2024 · Synced Jun 10, 2026, 4:04 AM EDT
Completed Phase 2 Interventional Results available

Tecemotide (L-BLP25) in Prostate Cancer

NCT01496131
View directory record Official record
Conditions
Prostate Cancer
Interventions
Radiation therapy, Goserelin, Cyclophosphamide, Tecemotide (L-BLP25)
Radiation · Drug
Lead sponsor
EMD Serono
Industry
Eligibility
18 Years and older · Male only
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
Rockland, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 8, 2018 · Synced Jun 10, 2026, 4:04 AM EDT
Not listed Phase 2 Interventional

Phase II High Risk Prostate Cancer Trial Using Gene & Androgen Deprivation Therapies, Radiotherapy, & Surgery

NCT03541928
View directory record Official record
Conditions
High-risk Prostate Cancer, Prostate Cancer
Interventions
HSV-Tk, Valacyclovir, Bicalutamide, Leuprolide Acetate, Brachytherapy, External beam radiotherapy, Radical prostatectomy
Drug · Radiation · Procedure
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
18 Years and older · Male only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 5, 2021 · Synced Jun 10, 2026, 4:04 AM EDT
Completed Phase 2 Interventional Results available

Androgen Deprivation Therapy and Vorinostat Followed by Radical Prostatectomy in Treating Patients With Localized Prostate Cancer

NCT00589472
View directory record Official record
Conditions
Prostate Adenocarcinoma, Stage I Prostate Cancer, Stage IIA Prostate Cancer, Stage IIB Prostate Cancer, Stage III Prostate Cancer
Interventions
Bicalutamide, Goserelin Acetate, Laboratory Biomarker Analysis, Leuprolide Acetate, Therapeutic Conventional Surgery, Vorinostat
Drug · Other · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
19 Years and older · Male only
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
15
States / cities
Los Angeles, California • San Francisco, California • Chicago, Illinois + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2017 · Synced Jun 10, 2026, 4:04 AM EDT
Completed Phase 1Phase 2 Interventional Results available

A Neoadjuvant Study of Androgen Ablation Combined With Cyclophosphamide and GVAX Vaccine for Localized Prostate Cancer

NCT01696877
View directory record Official record
Conditions
Prostate Cancer Adenocarcinoma in Situ
Interventions
degarelix acetate, Cyclophosphamide, GVAX
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
21 Years and older · Male only
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 27, 2019 · Synced Jun 10, 2026, 4:04 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Effect of Soy on Cognition and Hot Flashes in Men With Prostate Cancer Undergoing Testosterone Suppression Therapy

NCT00245518
View directory record Official record
Conditions
Hot Flashes
Interventions
Isoflavone, Placebos
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
21 Years and older · Male only
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2008
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 12, 2017 · Synced Jun 10, 2026, 4:04 AM EDT